AstraZeneca’s Farxiga combo shows promise at Phase 3 in late-stage chronic kidney disease
AstraZeneca took the opportunity at the digital ESC Congress 2020 over the weekend to reveal promising new Phase 3 data on the addition of Farxiga (dapagliflozin) to standard of care in reducing the risk of cardiovascular (CV) or renal death in patients with stage 2-4 chronic kidney disease (CKD).
The data was drawn from a study of 4,304 participants with stage 2-4 CKD and elevated urinary albumin excretion, harvested from trials across 21 countries. In these data, the drug combination was shown to reduce degradation of renal function or risk of CV or renal death by 39% compared to placebo, meeting its primary goal with consistent efficacy across patient populations both with and without type 2 diabetes.
Additionally, median time spent as a participant in the study was 2.4 years, and the absolute risk reduction conferred by the combo was shown to be 5.3% higher than this. All of the study’s secondary goals were also met, including a reduction in all-cause death of 31% compared to placebo.
“With today’s results, Farxiga becomes the first SGLT2 inhibitor proven to significantly prolong the survival of patients with chronic kidney disease with and without type 2 diabetes and we look forward to sharing these data with regulatory authorities around the world,” explained Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca. “Farxiga is also the first medicine in its class to demonstrate benefit in treating both heart failure and chronic kidney disease in patients with and without type 2 diabetes, and reduce the risk of hospitalisation for heart failure and nephropathy in type 2 diabetes.”
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …
AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …